Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26670523 | 0.78 | NPSR1 (0.34) | MEN1KMT2ANPSR1LMNA | |
| Bromide SCHEMBL26670486 | 0.76 | NPSR1 (0.33) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL1434492 | 0.76 | NPSR1 (0.38) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL11218074 | 0.75 | POLB (0.42) | MEN1KMT2ALMNATSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL1434491 | 0.75 | NPSR1 (0.36) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL27809338 | 0.74 | MEN1 (0.32) | MEN1KMT2ALMNA | |
| SCHEMBL3341865 | 0.74 | MEN1 (0.48) | MEN1KMT2ANPSR1LMNATSHR | |
| SCHEMBL21503963 | 0.73 | MEN1 (0.36) | MEN1KMT2ANPSR1LMNAPKM | |
| SCHEMBL1434628 | 0.73 | NPSR1 (0.39) | MEN1KMT2ANPSR1LMNACYP3A4 | |
| SCHEMBL1435953 | 0.73 | NPSR1 (0.44) | MEN1KMT2ANPSR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304420-B2 | prodrug of platelet lowering agent anagrelide, especially 3-and 5-substituted analogues with reduced potential for cardiovascular side-effects and better absorption from the GI tract; imidazo[2,1-b]quinazolin-2-one derivatives; megakaryocytopoeisis inhibitor; anticoagulant, antiproliferative agents | SHIRE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080176875-A1 | SUBSTITUTED QUINAZOLINES | SHIRE LLC (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176875-A1 | SUBSTITUTED QUINAZOLINES | MPL, ABL1, PDGFRA | MEN1 880/4885KMT2A 1455/4885NPSR1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.